East China Medicine gets skingee soft capsules exclusively promote the collection of collects

Home > Health

East China Medicine gets skingee soft capsules exclusively promote the collection of collects

2022-01-18 12:09:10 54 ℃

New Beijing News (Reporter Zhang Xiulan) Recently, East China Medicine Announced the Exclusive Market Proliferation of 27 Innovative Pharmaceutical Soft Capsules in the country in China, which is also the first new drug approved by the State Food and Drug Administration. Used to treat hepatocellular carcinoma. After the core product Akapo candies were set up, the layout of the "two legs" walking in East China is increasingly obvious. In addition to the exports of the hospital outside Akapo Sugar sales, commercial layouts continue to cover medical beauty, ADC (antibody coupling drugs), industrial microorganisms, etc., and achieve overseas licensing of drugs. According to East China Medicine, 2021 Akapo sugar collection price reduction is gradually rested.

East China Medicine January, disclosure, all-sized subsidiary Hangzhou Sino-US East China Pharmaceutical Co., Ltd. (hereinafter referred to as Sino-US East) and Beijing Shengoji Medical Technology Co., Ltd. (hereinafter referred to as Shengoji) wholly-owned subsidiary Beijing 珅Noki Pharmaceutical Technology Co., Ltd. (hereinafter referred to as Beijing Fukuki), Hainan Fukki Medical Technology Co., Ltd. (hereinafter referred to as Hainan Fuki) sign the product exclusive market promotion agreement (referred to as "cooperation agreement"), China and the United States have obtained small Molecular immune regulation of the exclusive market promotion of a type of innovative drug incense soft capsules in mainland China.

On January 10th, the State Food and Drug Administration approves the listing of eprostated sheliform soft capsules by prioritizing the approval procedures, which is used for non-suitable or patient refusal to accept standard treatment, and unevenness that has not received systemic treatment. Hepatocellular carcinoma, patient peripheral blood composite marker satisfies at least two of the test indicators: AFP ≥ 400 ng / ml; TNF-α <2.5pg / ml; IFN-γ ≥ 7.0 pg / ml. The drug is also the first drug approved by the State Food and Drug Administration, and Beijing Akochi holders for its listing permit.

Hepatocellular carcinoma is the main subtype of liver cancer, accounting for 85% -90%. According to the "Primary Liver Treatment Code (2019 Edition)" released by the National Health Department, primary liver cancer is the 4th common malignant tumors and the second tumor death caused by my country. The latest data released by the World Health Organization International Cancer Research Institute (IARC) shows that in 2020, my country's liver cancer has reached 400,000, accounting for 49.4% of global liver cancer, 391,000 deaths.

Frost & Sullivan predicts that in 2030, Chinese liver cancer will reach 526,000 cases. China's advanced hepatocyte cancer first-line treatment targeted drug market is also increased from 260 million yuan in 2014 to 810 million yuan in 2018, which will reach 16.07 billion yuan in 2030.

Take the promotion of the prostitute soft capsule, can bring more large-scale benefits to East China Medicine, and have to be verified by market.

"Two legs" walk, net profit slow down again

In the second batch of national drug collection, the price of Akapo candidates exceeded 90%. Since Sino-US East China main products Akapo candidate collection, sales are affected, so East China is beginning to "two legs" walk, while the grassroots, adjournment and retail markets focus on the development of pharmaceutical business and medical products.

In February 2021, East China Medicine British Sinclair, with a total of 65 million euros of equity, with a maximum of $ more than 20 million euros, and acquired the Spanish Energy Source Type Medical Machinery Company, which Cocoon, who holds Cocoon. 100% stake. On the month, East China Medicine won the US Provendion Bio's exclusive clinical development and commercial rights and interests in the research product PRV-3279; in April, invested Noba, the 75% stake in Daool creature was acquired, and became its controlling shareholder; June Cooperate with Japan Schihia to obtain an exclusive development, production and commercial interest in 25 Asia-Pacific countries and regions such as SCO-094 in China.

In September 202, East China Medicine realized the first overseas licensed, awarded Korea Daewon Clinical II in the research product TTP273 in Korea's exclusive development, production and commercial rights; East China Medicine, then announced the US ASHVATTHA company, 80 in research Products in 20 Asian countries and regions such as China, Singapore, Malaysia and regions. In December, East China Pharmaceutical announced that the US key single-arm clinical trial developed in the development of antibody coupling drugs (ADC) IMGN853 in US Immunogen has reached the main research terminal, and it is expected to submit a biological product license application in the United States this year (BLA) .

Under a series of operations, in the first three quarters of 2021, East China Medicine Net Profit was gradually narrowed, 33.90%, 24.89%, 20.74%, respectively. At the investor exchange meeting in January 2022, East China Medicine said that in 2021, the company Akapo sugar tablets, injection of pantotrazole sodium production and the new medical insurance payment price of the Yibei capsules pay for business income. The impact is gradually digesting.

School of proofing